4.6 Review

Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease

期刊

CYTOKINE & GROWTH FACTOR REVIEWS
卷 26, 期 6, 页码 625-635

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2015.07.016

关键词

Fibroblast growth factor 15/19; Bile acid signaling; Nuclear receptors; Liver disease; Obesity; Energy metabolism

资金

  1. Schweizerischer Nationalfonds SNF [310030_135548]
  2. Else Kroner-Fresenius-Stiftung EKFS [2014_A67]
  3. Deutsche Forschungsgemeinschaft [SFB 688, TP A20]
  4. IZKF Wurzburg [A-242]
  5. Faculty of Medicine of the University of Wurzburg
  6. Swiss National Science Foundation (SNF) [310030_135548] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

The gut-derived hormone fibroblast growth factor 15/19 (FGF15/19) is an emerging versatile regulator of various metabolic pathways. As such, FGF15/19 has been implicated in homeostatic control of bile acid, carbohydrate and lipid metabolism in multiple target organs including the liver, adipose tissue and brain. In line with this, growing evidence suggests that dysregulation of FGF15/19 contributes to a number of metabolic and bile acid-associated disorders such as fatty liver disease, Type 2 diabetes and different gastrointestinal dysfunctions. In this review we summarize the current knowledge on the organ-specific functions of FGF15/19 and address their underlying molecular mechanisms. Moreover, recent advances in the characterization of factors that control the release of the hormone in the gut will be discussed and linked to the current view of how alterations of FGF15/19 signaling may contribute to disease development. Finally, the suitability of FGF15/19 as a potential therapeutic target will be critically reviewed. (C) 2015 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers

Marcin Krawczyk, Heike Bantel, Monika Rau, Joern M. Schattenberg, Frank Gruenhage, Anita Pathil, Muenevver Demir, Johannes Kluwe, Tobias Boettler, Susanne N. Weber, Andreas Geier, Frank Lammert

JOURNAL OF HUMAN GENETICS (2018)

Article Multidisciplinary Sciences

Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective

Ali Canbay, Julia Kaelsch, Ursula Neumann, Monika Rau, Simon Hohenester, Hideo A. Baba, Christian Rust, Andreas Geier, Dominik Heider, Jan-Peter Sowa

PLOS ONE (2019)

Article Gastroenterology & Hepatology

Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness

Stephanie Liebig, Neele Stoeckmann, Andreas Geier, Monika Rau, Joern M. Schattenberg, Matthias J. Bahr, Michael P. Manns, Elmar Jaeckel, Klaus Schulze-Osthoff, Heike Bantel

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2019)

Article Gastroenterology & Hepatology

A 2-step fast-track elastometry service for advanced workup of nonalcoholic fatty liver disease (NAFLD) patients - single-center real-world experience of outpatient clinical practice

Mohamed Alsenbesy, Monika Rau, Johannes Weiss, Oliver Goetze, Andreas Geier

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2019)

Review Pharmacology & Pharmacy

An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy

Monika Rau, Andreas Geier

Summary: NAFLD is a recognized disease entity with increasing prevalence. Regulatory agencies have identified an unmet medical need for NASH treatment and initiated expedited drug development. Current research focuses on drugs with metabolic, anti-inflammatory, and anti-fibrotic effects for treating NASH, with a potential future for combination therapy.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

Article Medicine, Research & Experimental

Protein Kinase D2 drives chylomicron-mediated lipid transport in the intestine and promotes obesity

Jonathan Trujillo-Viera, Rabih El-Merahbi, Vanessa Schmidt, Till Karwen, Angel Loza-Valdes, Akim Strohmeyer, Saskia Reuter, Minhee Noh, Magdalena Wit, Izabela Hawro, Sabine Mocek, Christina Fey, Alexander E. Mayer, Mona C. Loeffler, Ilka Wilhelmi, Marco Metzger, Eri Ishikawa, Sho Yamasaki, Monika Rau, Andreas Geier, Mohammed Hankir, Florian Seyfried, Martin Klingenspor, Grzegorz Sumara

Summary: The study reveals the significant role of protein kinase D2 in lipid absorption, where its activity promotes TG transfer within enterocytes, affecting the development of obesity and diabetes. This finding suggests that targeting PKD2 may hold promise as a therapeutic approach for obesity.

EMBO MOLECULAR MEDICINE (2021)

Review Gastroenterology & Hepatology

Screening for nonalcoholic fatty liver disease-when, who and how?

Christoph G. Dietrich, Monika Rau, Andreas Geier

Summary: NAFLD is a common liver disease, especially prevalent in patients with metabolic syndrome and in Western countries. Complications include fibrosis, cirrhosis, hepatocellular carcinoma, as well as increased risk for cardiovascular disease, extrahepatic neoplasia, and other organ damage.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

Article Multidisciplinary Sciences

Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry

Monika Rau, Peter Buggisch, Stefan Mauss, Klaus H. W. Boeker, Hartwig Klinker, Tobias Mueller, Albrecht Stoehr, Jorn M. Schattenberg, Andreas Geier

Summary: Liver steatosis in chronic HCV infection does not appear to contribute significantly to fibrosis progression in this unique cohort.

PLOS ONE (2022)

Article Medicine, General & Internal

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4

Katharina John, Martin Franck, Sherin Al Aoua, Monika Rau, Yvonne Huber, Joern M. Schattenberg, Andreas Geier, Matthias J. Bahr, Heiner Wedemeyer, Klaus Schulze-Osthoff, Heike Bantel

Summary: The combination of FIB-4 and M30 allows for a more reliable identification of patients at risk for progressed NAFLD and has the potential to improve patient stratification.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Gastroenterology & Hepatology

Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations

Florian P. Reiter, Monika Rau, Volker Kunzmann, Ralph Kickuth, Ingo Klein, Olaf Neumann, Albrecht Stenzinger, Peter Schirmacher, Andreas Geier

Summary: Immunotherapy has shown promising efficacy in late-line treatment of advanced HCC, even in fourth-line scenarios. Established biomarkers predicting response to immunotherapy were not detected in this case, but mutations in SETD2 and LRP1B genes may explain the exceptional response.

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2023)

Article Gastroenterology & Hepatology

Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry

Andreas Geier, Monika Rau, Anita Pathil-Warth, Manfred von der Ohe, Joern Schattenberg, Nektarios Dikopoulos, Kerstin Stein, Yvonne Serfert, Thomas Berg, Peter Buggisch, Muenevver Demir, Elke Roeb, Bianka Wiebner, Heiner Wedemeyer, Stefan Zeuzem, Wolf P. Hofmann

Summary: The German NAFLD-Registry is a prospective study that aims to describe clinical characteristics and observe outcomes in patients with NAFLD. From the baseline data of the first 501 patients, it was found that approximately 13% had a high risk for advanced fibrosis, about one-third had a liver stiffness value greater than 9.6kPa, and 10% had a clinical diagnosis of liver cirrhosis. Comorbidities such as arterial hypertension, hypercholesterolemia, and type 2 diabetes mellitus were more prevalent in high-risk patients.

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2023)

Article Nutrition & Dietetics

Salt-Intake-Related Behavior Varies between Sexes and Is Strongly Associated with Daily Salt Consumption in Obese Patients at High Risk for MASLD

Bianca Heller, Florian P. Reiter, Hans Benno Leicht, Cornelia Fiessler, Ina Bergheim, Peter U. Heuschmann, Andreas Geier, Monika Rau

Summary: The study reveals a strong link between daily salt intake and salt-intake-related behavior, with sex-specific differences in an MASLD cohort. Specific behavioral approaches, such as improving salt awareness, may enhance adherence to lifestyle changes in male patients in high cardiovascular risk populations.

NUTRIENTS (2023)

Meeting Abstract Gastroenterology & Hepatology

NAFLD patients scheduled for bariatric surgery present with a milder disease phenotype as compared to not morbidly obese NAFLD patients: analysis of a large real-world cohort

Monika Rau, Sarah Kaps, Hans Benno Leicht, Florian P. Reiter, Marcin Krawczyk, Andreas Geier

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Elevated serum bile acids in NASH patients with fibrosis in the context of their cholestatic genetic predisposition

Monika Rau, Theresa Schmitt, Marcin Krawczyk, Luetjohann Dieter, Maria Monte, Jose Marin, Andreas Geier

JOURNAL OF HEPATOLOGY (2021)

Article Gastroenterology & Hepatology

Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease

Monika Rau, Ateequr Rehman, Marcus Dittrich, Albert K. Groen, Heike M. Hermanns, Florian Seyfried, Niklas Beyersdorf, Thomas Dandekar, Philip Rosenstiel, Andreas Geier

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2018)

暂无数据